Is Krystal Biotech, Inc. Common Stock a growth stock? A data-driven read on its earnings momentum, price leadership, and demand, scored against every US stock from SEC filings and daily prices, and re-ranked after every close.
Yes, KRYS fits the growth-stock profileAs of the 2026-07-27 close, KRYS scores 94 out of 99 on our growth-stock rating, a textbook growth-stock leader. That ranks it 37th of 4,897 rated US stocks, the top 1% of the market.
Its strongest trait is A (annual earnings growth) at 83, and its weakest is N (new highs & catalysts) at 43. KRYS clears 5 of the six core growth traits we score per stock; the seventh, overall market direction, is judged market-wide.
On price, KRYS carries an elite Relative Strength rating of 93, meaning it has outperformed about 93% of the market over the past year.
Underneath the score: quarterly earnings up 53% year over year, sales up 32%, trading 7% below its 52-week high.
The six traits that separate real growth stocks from the rest: earnings, price leadership, and demand. Each is scored 1–99 against the whole US market. We compute them with the CANSLIM method, double-weighting earnings and relative strength.
| C | Current quarterly earnings most recent EPS growth vs. a year ago |
76 |
| A | Annual earnings growth multi-year earnings trend |
83 |
| N | New highs & catalysts proximity to new 52-week highs |
43 |
| S | Supply & demand volume behind the move vs. share supply |
64 |
| L | Leader or laggard Relative Strength within its group |
67 |
| I | Institutional sponsorship fund accumulation and 13F ownership |
65 |
KRYS shows the earnings strength and price leadership that define a growth stock. That is what our screen flags, not a recommendation to buy. Timing and market direction still matter.
The stocks ranking above KRYS today, the growth leaders you’d weigh against it.
Where KRYS sits in its base, its 52-week path, and the trait trend over the past year.
Every US stock scored on the traits that define a growth stock and re-ranked after each close, with the top ranks, the full trait breakdown, and today’s market read.
Open the app, free through September 1Yes, KRYS fits the growth-stock profile. KRYS shows the earnings strength and price leadership that define a growth stock. That is what our screen flags, not a recommendation to buy. Timing and market direction still matter.
Krystal Biotech, Inc. Common Stock (KRYS) scores 94 out of 99 on our growth-stock rating as of the 2026-07-27 close, ranking 37th of 4,897 rated US stocks.
KRYS's most recent quarterly earnings were up about 53% year over year, with sales up 32%.
KRYS has a Relative Strength rating of 93, meaning it has outperformed roughly 93% of the US market over the trailing year.
Create a free Growth Stock Analyzer account to see where KRYS ranks against every US stock, the stronger growth stocks to weigh against it, and its full price and earnings history.
Want the method behind the score? Read how we grade growth stocks with CANSLIM.